AU2008207948A1 - Use of antibody conjugates - Google Patents

Use of antibody conjugates Download PDF

Info

Publication number
AU2008207948A1
AU2008207948A1 AU2008207948A AU2008207948A AU2008207948A1 AU 2008207948 A1 AU2008207948 A1 AU 2008207948A1 AU 2008207948 A AU2008207948 A AU 2008207948A AU 2008207948 A AU2008207948 A AU 2008207948A AU 2008207948 A1 AU2008207948 A1 AU 2008207948A1
Authority
AU
Australia
Prior art keywords
cancer
antibody
biologically active
mab
active molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008207948A
Other languages
English (en)
Inventor
Richard H. Weisbart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Veterans Affairs
Original Assignee
United States Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Veterans Affairs filed Critical United States Department of Veterans Affairs
Publication of AU2008207948A1 publication Critical patent/AU2008207948A1/en
Assigned to DEPARTMENT OF VETERANS AFFAIRS reassignment DEPARTMENT OF VETERANS AFFAIRS Alteration of Name(s) of Applicant(s) under S113 Assignors: DEPARTMENT OF VETERANS AFFAIRS, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008207948A 2007-01-22 2008-01-22 Use of antibody conjugates Abandoned AU2008207948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89701207P 2007-01-22 2007-01-22
US60/897,012 2007-01-22
PCT/US2008/051734 WO2008091911A2 (en) 2007-01-22 2008-01-22 Use of antibody conjugates

Publications (1)

Publication Number Publication Date
AU2008207948A1 true AU2008207948A1 (en) 2008-07-31

Family

ID=39645132

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008207948A Abandoned AU2008207948A1 (en) 2007-01-22 2008-01-22 Use of antibody conjugates

Country Status (6)

Country Link
US (2) US20100143358A1 (enExample)
EP (1) EP2109625A4 (enExample)
JP (1) JP2010516708A (enExample)
AU (1) AU2008207948A1 (enExample)
CA (1) CA2676234A1 (enExample)
WO (1) WO2008091911A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
CA2777486A1 (en) 2008-10-15 2010-04-22 4S3 Bioscience Inc. Methods and compositions for treatment of myotonic dystrophy
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
JP6178785B2 (ja) * 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
CA2832184A1 (en) * 2011-04-07 2012-10-11 Memorial Sloan Kettering Cancer Center Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US12195550B2 (en) * 2012-03-30 2025-01-14 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US20150152170A1 (en) * 2012-05-23 2015-06-04 Valerion Therapeutics, Llc Methods for increasing muscle contractility
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス， エルエルシー ポンぺ病の処置のための方法および組成物
WO2015106290A1 (en) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
WO2015134607A1 (en) 2014-03-04 2015-09-11 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
SG11201803768WA (en) 2015-10-08 2018-06-28 Univ Utah Res Found Methods and compositions for preventing or treating cancer
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
CN111316099A (zh) 2017-07-12 2020-06-19 约翰霍普金斯大学 用于1型糖尿病诊断的基于脂蛋白体的znt8自身抗原
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
WO2020037174A1 (en) 2018-08-16 2020-02-20 The Johns Hopkins University Antibodies to human znt8
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
KR20220101073A (ko) 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
AU2022328714A1 (en) * 2021-08-20 2024-02-29 The Johns Hopkins University Cell-surface antibody to a specific biomarker of pancreatic beta-cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) * 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
WO1997032602A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
WO2001019393A1 (en) * 1999-09-13 2001-03-22 Cornell Research Foundation, Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems

Also Published As

Publication number Publication date
WO2008091911A8 (en) 2008-12-18
JP2010516708A (ja) 2010-05-20
WO2008091911A3 (en) 2008-11-06
US20170096497A1 (en) 2017-04-06
EP2109625A4 (en) 2011-06-08
CA2676234A1 (en) 2008-07-31
US20100143358A1 (en) 2010-06-10
EP2109625A2 (en) 2009-10-21
WO2008091911A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
US20170096497A1 (en) Use of antibody conjugates
US7189396B1 (en) Delivery system using mAb 3E10 and mutants and/or functional fragments thereof
CN102281890B (zh) Sparc结合肽及其应用
JP6728264B2 (ja) 抗ｈｅｒ２抗体及びその結合体
KR101754433B1 (ko) 항-ｃｄ100 항체 및 이의 사용 방법
JP6242484B2 (ja) 特定の改善されたヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
JP6154895B2 (ja) ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
JP4398644B2 (ja) ＥｒｂＢ界面ペプチド擬態およびその使用方法
EP3655432A1 (en) Binding proteins 1
RS51898B (sr) Specifični agensi koji vezuju humani angiopoetin-2
CN102281891A (zh) 白蛋白结合肽介导的疾病靶向
US20240092860A1 (en) Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
US11208494B2 (en) Monoclonal antibodies specific to the plexin-semaphorin-integrin (PSI) domain of RON for drug delivery and its application in cancer therapy
CN116134138A (zh) 靶向细胞内诱瘤蛋白的抗体、或其单链可变片段与癌细胞穿透肽的融合蛋白、及其用途
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
CA3232777A1 (en) Novel interferon variants and bifunctional fusion molecules thereof
CN110627905A (zh) 靶向vegf与egfr的双功能融合蛋白及其应用
KR20190080809A (ko) 세포질 침투 항체에 융합된 rna 분해효소를 포함하는 면역독소
JP2010077026A (ja) がん関連マクロファージを標的とした固形がん治療剤
KR101854529B1 (ko) 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
US20100266592A1 (en) Therapeutic antennapedia-antibody molecules and methods of use thereof
EP1764113A1 (en) Antibodies against lung cancer, antigens and methods of use thereof for treating lung cancer
JP5896568B2 (ja) 動脈硬化又は動脈硬化性疾患の治療剤、及び動脈硬化又は動脈硬化性疾患の診断薬
RU2822497C1 (ru) Конъюгат антитело против c-met-лекарственное средство и его применение
KR20230131448A (ko) VEGF-Grab 및 PD-1 또는 PD-L1 길항제를 포함하는 병용 투여용 조성물

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND APPLICANT NAME FROM TO THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted